[ad_1]
Stockholm, December 10, 2021 /PRNewswire/ – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotechnology company focusing on the research and development of refractory blood disease therapies, announced today that the company will show three presentations about meflufen (INN melphalan fluorine). Fenamine) at the annual meeting of the American Society of Hematology, ASH, at December 11-14, exist Atlanta, Georgia, U.S., America.
“We are committed to collecting and sharing updated data on Melflufen with the myeloma community,” said Clas Baker, MD, PhD, Executive Vice President and Chief Medical Officer. “Continuous understanding of the safety and efficacy data for patients with relapsed and refractory multiple myeloma is essential to guide the further clinical development of the PDC platform.”
The following is a brief description of abstracts that have been accepted by the American Society of Hematology. The abstract is available online: https://ashpublications.org.
|
Clinical abstracts |
First author |
Issue number |
Dispose of |
|
|
The full story on Benzinga.com
[ad_2]
Source link
